Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

Clinical trial NCT06091124 · RECRUITING

Trial details

NCT number: NCT06091124
Sponsor: RenJi Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Carcinoma of the Bladder Bladder Cancer

Start date: 2023-11-16
Primary completion: 2027-01-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.